1. Signaling Pathways
  2. Protein Tyrosine Kinase/RTK
  3. Src
  4. Src Isoform
  5. Src Inhibitor

Src Inhibitor

Src Inhibitors (132):

Cat. No. Product Name Effect Purity
  • HY-108485
    Damnacanthal
    Inhibitor ≥98.0%
    Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of p56lck tyrosine kinase activity. Natural Damnacanthal inhibits p56 lck autophosphorylation and phosphorylation of exogenous substrates with IC50s of 46 nM and 220 nM, respectively. Damnacanthal is a potent inducer of apoptosis with anticancer activity. Damnacanthal also has antinociceptive, anti-inflammatory effects in mice and anti-fungal activity against Candida albicans.
  • HY-127002
    Squarunkin A
    Inhibitor 99.34%
    Squarunkin A is a potent and selective UNC119-cargo interaction inhibitor, interrupting the UNC119A-myristoylated Src N-terminal peptide interaction (IC50=10 nM). Squarunkin A interferes with the activation of Src kinase in cells.
  • HY-15805
    KIN-8194
    Inhibitor 98.01%
    KIN-8194 is an orally active dual inhibitor of HCK and BTK, with IC50 values of 0.915 and <0.495 nM, respectively. KIN-8194 impairs growth and integrin-mediated adhesion of BTKi-resistant mantle cell lymphoma (MCL). KIN-8194 overcomes ibrutinib (HY-10997) resistance with a survival benefit in TMD-8 ABC DLBCL xenografted mice.
  • HY-13941B
    1-Naphthyl PP1 hydrochloride
    Inhibitor 99.83%
    1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) is a selective inhibitor of src family kinases. 1-Naphthyl PP1 hydrochloride inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively.
  • HY-10158A
    Bosutinib hydrate
    Inhibitor 99.97%
    Bosutinib hydrate is an oraly activel Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively.
  • HY-10181S
    Dasatinib-d8
    Inhibitor 98.17%
    Dasatinib-d8 is a deuterium labeled Dasatinib. Dasatinib is a dual Bcr-Abl and Src family tyrosine kinase inhibitor.
  • HY-N4201
    β-Hydroxyisovalerylshikonin
    Inhibitor 99.83%
    Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermum erythrorhizon, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC50s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells.
  • HY-N6596
    7-Hydroxy-4H-chromen-4-one
    Inhibitor 99.94%
    7-Hydroxychromone is a Src kinase inhibitor with an IC50 of <300 μM.
  • HY-108016
    Peruvoside
    Inhibitor 99.32%
    Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib.
  • HY-132150A
    HPK1-IN-2 dihydrochloride
    Inhibitor 98.69%
    HPK1-IN-2 dihydrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50<0.05 µΜ) with antitumor activity. HPK1-IN-2 dihydrochloride also inhibits Lck (0.05 µΜ<IC50<0.5 µΜ) and Flt3 (IC50<0.05 µΜ) kinase activities.
  • HY-W744699
    Larixol
    Inhibitor
    Larixol is an fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Larixol can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Larixol inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM), cathepsin G release (IC50: 2.76 μM), and chemotaxis. Larixol improves neutrophil hyperactivation and reduces inflammation or tissue damage. A series of Larixol derivatives were found to have inhibitory effects on FSGS-related TRPC6 functional mutants.
  • HY-111187
    KX2-361
    Inhibitor 99.55%
    KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 shows good oral bioavailability and readily crosses the BBB in mice. KX2-361 shows anti-tumor activity and induces apoptosis of Glioblastoma (GBM) cell.
  • HY-123506
    Fenlean
    Inhibitor 99.56%
    Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean can inhibit over-activated microglia and protect dopaminergic neurons. Fenlean can attenuate neuroinflammation in Parkinson's disease models.
  • HY-18237
    KX1-004
    Inhibitor 99.75%
    KX1-004 is a potent and non-ATP competitive Src-PTK inhibitor with an IC50 of 40 μM. KX1-004 protects the cochlea from hazardous noise and prevents noise-induced hearing loss (NIHL).
  • HY-136849
    TL13-68
    Inhibitor 98.88%
    TL13-68 is a biotin-tagged version of SM1-71, and it can be used to research the mechanism of SM1-71.
  • HY-10234A
    Saracatinib difumarate
    Inhibitor 99.24%
    Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .
  • HY-123298
    Chrysotoxine
    Inhibitor 99.52%
    Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research.
  • HY-15764G
    A 419259 (GMP)
    Inhibitor
    A 419259 GMP is the GMP grade A 419259 (HY-15764), inducing cell apoptosis. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. A 419259 (RK-20449) is a broad-spectrum pyrrole-pyrimidine inhibitor targeting Src, Lck, and Lyn with IC50s of 9 nM, <3 nM, and <3 nM, respectively.
  • HY-155587
    Hydroxy-PP
    Inhibitor 99.66%
    Hydroxy-PP is a potent CBR1 inhibitor with an IC50 value of 0.78 μM. Hydroxy-PP also potently inhibits the cytoplasmic tyrosine kinase Fyn with an IC50 value of 5 nM.
  • HY-156914
    IGF-1R/SRC-IN-1
    Inhibitor 99.86%
    IGF-1R/SRC-IN-1 (Compound 3b) is an inhibitor for IGF-1R (IC50 is 63 μM) and SRC.